Nat Rev Cancer. 2006 Apr;6(4):321-30.

Targeting polo-like kinase 1 for cancer therapy.

Source

Department of Obstetrics and Gynecology, School of Medicine, J.W. Goethe-University, Theodore-Stern-Kai 7, 60590 Frankfurt, Germany. Strebhardt@em.uni-frankfurt.de

Abstract

Human polo-like kinase 1 (PLK1) is essential during mitosis and in the maintenance of genomic stability. PLK1 is overexpressed in human tumours and has prognostic potential in cancer, indicating its involvement in carcinogenesis and its potential as a therapeutic target. The use of different PLK1 inhibitors has increased our knowledge of mitotic regulation and allowed us to assess their ability to suppress tumour growth in vivo. We address the structural features of the kinase domain and the unique polo-box domain of PLK1 that are most suited for drug development and discuss our current understanding of the therapeutic potential of PLK1.

PMID:: 16557283; [PubMed - indexed for MEDLINE]

LinkOut - more resources

Full Text Sources

Other Literature Sources

Labome Researcher Resource - ExactAntigen/Labome

Medical

Supplemental Content

Save items

Related citations in PubMed

The natural product Aristolactam AIIIa as a new ligand targeting the polo-box domain of polo-like kinase 1 potently inhibits cancer cell proliferation. [Acta Pharmacol Sin. 2009]
The natural product Aristolactam AIIIa as a new ligand targeting the polo-box domain of polo-like kinase 1 potently inhibits cancer cell proliferation.
Li L, Wang X, Chen J, Ding H, Zhang Y, Hu TC, Hu LH, Jiang HL, Shen X. Acta Pharmacol Sin. 2009 Oct; 30(10):1443-53.
Polo-like kinase 1 (Plk1) is expressed by cutaneous T-cell lymphomas (CTCLs), and its downregulation promotes cell cycle arrest and apoptosis. [Cell Cycle. 2011]
Polo-like kinase 1 (Plk1) is expressed by cutaneous T-cell lymphomas (CTCLs), and its downregulation promotes cell cycle arrest and apoptosis.
Nihal M, Stutz N, Schmit T, Ahmad N, Wood GS. Cell Cycle. 2011 Apr 15; 10(8):1303-11. Epub 2011 Apr 15.
Inhibition of polo-like kinase 1 leads to the suppression of osteosarcoma cell growth in vitro and in vivo. [Anticancer Drugs. 2011]
Inhibition of polo-like kinase 1 leads to the suppression of osteosarcoma cell growth in vitro and in vivo.
Liu X, Choy E, Harmon D, Yang S, Yang C, Mankin H, Hornicek FJ, Duan Z. Anticancer Drugs. 2011 Jun; 22(5):444-53.
Review Polo on the Rise-from Mitotic Entry to Cytokinesis with Plk1. [Dev Cell. 2008]
Review Polo on the Rise-from Mitotic Entry to Cytokinesis with Plk1.
Petronczki M, Lénárt P, Peters JM. Dev Cell. 2008 May; 14(5):646-59.
Review Plk1-targeted small molecule inhibitors: molecular basis for their potency and specificity. [Mol Cells. 2011]
Review Plk1-targeted small molecule inhibitors: molecular basis for their potency and specificity.
Murugan RN, Park JE, Kim EH, Shin SY, Cheong C, Lee KS, Bang JK. Mol Cells. 2011 Sep; 32(3):209-20. Epub 2011 Jul 29.

See reviews... See all...

Cited by 64 PubMed Central articles

Computational design of targeted inhibitors of polo-like kinase 1 (plk1). [Bioinform Biol Insights. 2012]
Computational design of targeted inhibitors of polo-like kinase 1 (plk1).
Jani KS, Dalafave DS. Bioinform Biol Insights. 2012; 6:23-31. Epub 2012 Feb 20.
Phase i study of the Plk1 inhibitor BI 2536 administered intravenously on three consecutive days in advanced solid tumours. [Curr Oncol. 2012]
Phase i study of the Plk1 inhibitor BI 2536 administered intravenously on three consecutive days in advanced solid tumours.
Frost A, Mross K, Steinbild S, Hedbom S, Unger C, Kaiser R, Trommeshauser D, Munzert G. Curr Oncol. 2012 Feb; 19(1):e28-35.
Combined Pharmacophore Modeling, Docking, and 3D-QSAR Studies of PLK1 Inhibitors. [Int J Mol Sci. 2011]
Combined Pharmacophore Modeling, Docking, and 3D-QSAR Studies of PLK1 Inhibitors.
Lu S, Liu HC, Chen YD, Yuan HL, Sun SL, Gao YP, Yang P, Zhang L, Lu T. Int J Mol Sci. 2011; 12(12):8713-39. Epub 2011 Dec 1.

See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Targeting polo-like kinase 1 for cancer therapy.
Targeting polo-like kinase 1 for cancer therapy.
Nat Rev Cancer. 2006 Apr ;6(4):321-30.

PubMed
Guideline improved dentists' knowledge but not their clinical decision-making sk...
Guideline improved dentists' knowledge but not their clinical decision-making skills.
Evid Based Dent. 2006 ;7(1):8.

PubMed
Pegylated interferon plus ribavirin for chronic hepatitis C: the role of combina...
Pegylated interferon plus ribavirin for chronic hepatitis C: the role of combination therapy today, tomorrow and in the future.
Minerva Gastroenterol Dietol. 2006 Jun ;52(2):157-74.

PubMed
Fractures of the distal tibial metaphysis in children: patterns of injury and re...
Fractures of the distal tibial metaphysis in children: patterns of injury and results of treatment.
J Pediatr Orthop. 2006 Mar-Apr ;26(2):171-6.

PubMed
M-Coffee: combining multiple sequence alignment methods with T-Coffee.
M-Coffee: combining multiple sequence alignment methods with T-Coffee.
Nucleic Acids Res. 2006 Mar 23 ;34(6):1692-9. Print 2006 .

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to:

Targeting polo-like kinase 1 for cancer therapy.

Source

Abstract

Publication Types, MeSH Terms, Substances

Publication Types

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Supplemental Content

Save items

Related citations in PubMed

Cited by 64 PubMed Central articles

Related information

Recent activity

Simple NCBI Directory

Getting Started

Resources

Popular

Featured

NCBI Information